Association of interleukin-17A and chemokine/vascular endothelial growth factor-induced angiogenesis in newly...

Area of Science:

• Oncology
• Immunology

Background:

• The Interleukin-17 (IL-17) cytokine family and its receptors play complex roles in human malignancies, potentially supporting or inhibiting tumor growth.
• Understanding the specific roles of IL-17 family members and associated signaling molecules in bladder cancer (BC) is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the expression of CXCR2, IL-17RA, and IL-17RC genes at the mRNA level in bladder cancer patients.
• To quantify the tissue and serum levels of IL-17A, vascular endothelial growth factor (VEGF), and transforming growth factor β (TGF-β) in bladder cancer patients compared to controls.

Main Methods:

• Gene expression analysis of CXCR2, IL-17RA, and IL-17RC in tumor and normal tissues.
• Measurement of serum and tissue concentrations of IL-17A, VEGF, and TGF-β using appropriate assays.

Main Results:

• Significant upregulation of IL-17RA, IL-17RC, and CXCR2 gene expression was observed in bladder cancer tumoral tissues compared to normal tissues.
• Distinct differences in serum and tissue concentrations of IL-17A, VEGF, and TGF-β were found between bladder cancer patients and the control group, as well as between tumor and normal tissues.

Conclusions:

• Bladder cancer is associated with significant dysregulation of CXCR2, IL-17RA, and IL-17RC gene expression.
• Altered levels of IL-17A, VEGF, and TGF-β in bladder cancer patients suggest their involvement in disease development.
• These findings highlight the potential of targeting the IL-17 pathway, CXCR2, VEGF, and TGF-β for bladder cancer diagnosis and therapy.